The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy
Open accessAbstract
High activity of histone deacetylases (HDACs) causes epigenetic alterations associated with malignant cell behaviour. Consequently, HDAC inhibitors have entered late-phase clinical trials as new antineoplastic drugs. However, little is known about expression and function of specific HDAC isoforms in human tumours including prostate cancer. We investigated the expression of class I HDACs in 192 prostate carcinomas by immunohistochemistry and correlated our findings to clinicopathological parameters including follow-up data. Class I HDAC isoforms were strongly expressed in the majority of the cases (HDAC1: 69.8%, HDAC2: 74%, HDAC3: 94.8%). High rates of HDAC1 and HDAC2 expression were significantly associated with tumour dedifferentiation. Strong expression of all HDACs was accompanied by enhanced tumour cell proliferation. In addition, HDAC2 was an independent prognostic marker in our prostate cancer cohort. In conclusion, we showed that the known effects of HDACs on differentiation and proliferation of cancer cells observed in vitro can also be confirmed in vivo. The class I HDAC isoforms 1, 2 and 3 are differentially expressed in prostate cancer, which might be important for upcoming studies on HDAC inhibitors in this tumour entity. Also, the highly significant prognostic value of HDAC2 clearly deserves further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439 · cited 3×
“…22 January 2008 & 2008 Cancer Research UK Keywords: HDAC; prostate cancer; prognostic marker; immunohistochemistry Prostate cancer is the most common malignant neoplasm in men and ranks second only to lung cancer as a cause of tumour-related death of males in the United States (Jemal et al, 2007).”
BackgroundInfluentialHistone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Epigenetic therapy of cancer: past, present and future
Yoo, C. B., & Jones, P. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1930 · Cited by 1,289
Postoperative Nomogram for Disease Recurrence After Radical Prostatectomy for Prostate Cancer
Kattan, M. W., Wheeler, T. M., & Scardino, P. T. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1499 · Cited by 741
Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes
Kim, M. S., Kwon, H. J., Lee, Y. M., Baek, J. H., Jang, J.-E., Lee, S.-W., Moon, E.-J., Kim, H.-S., Lee, S.-K., Chung, H. Y., et al. (2001) · Nature Medicine · doi:10.1038/86507 · Cited by 731
Butler, L. M., Agus, D. B., Scher, H. I., Higgins, B., Rose, A., Cordon‐Cardo, C., Thaler, H. T., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2000) · PubMed · Cited by 615
Wilson, A. J., Byun, D.-S., Popova, N., Murray, L. B., L'Italien, K., Sowa, Y., Arango, D., Velcich, A., Augenlicht, L. H., & Mariadason, J. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510023200 · Cited by 575 · cited 2×
“An important role of class I HDACs, especially HDAC3, on cell proliferation has also been reported for other tumour entities (Wilson et al, 2006), which again makes it an interesting therapy target.”
BackgroundUpregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer
Halkidou, K., Gaughan, L., Cook, S., Leung, H. Y., Neal, D. E., & Robson, C. N. (2004) · The Prostate · doi:10.1002/pros.20022 · Cited by 509
CLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS AS ANTICANCER AGENTS
Drummond, D. C., Noble, C. O., Kirpotin, D. B., Guo, Z., Scott, G. K., & Benz, C. C. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095825 · Cited by 494
Münster, P. N., Troso-Sandoval, T. A., Rosen, N. X., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2001) · PubMed · Cited by 402
Myzak, M. C., Hardin, K., Wang, R., Dashwood, R. H., & Ho, E. (2006) · Carcinogenesis · doi:10.1093/carcin/bgi265 · Cited by 306
Epigenetic Changes in Prostate Cancer: Implication for Diagnosis and Treatment
Li, L.-C., Carroll, P. R., & Dahiya, R. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji010 · Cited by 299
Qian, D. Z., Kato, Y., Shabbeer, S., Wei, Y., Verheul, H. M. W., Salumbides, B., Sanni, T., Atadja, P., & Pili, R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1132 · Cited by 268
Modulation of radiation response by histone deacetylase inhibition
Chinnaiyan, P., Vallabhaneni, G., Armstrong, E., Huang, S.-M., & Harari, P. M. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.12.088 · Cited by 243
Iljin, K., Wolf, M., Edgren, H., Gupta, S., Kilpinen, S., Skotheim, R. I., Peltola, M., Smit, F., Verhaegh, G., Schalken, J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1986 · Cited by 241
Histone Deacetylase Inhibitors Have a Profound Antigrowth Activity in Endometrial Cancer Cells
Takai, N., Desmond, J. C., Kumagai, T., Gui, D., Said, J. W., Whittaker, S., Miyakawa, I., & Koeffler, H. P. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0100 · Cited by 233
Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis
Krusche, C. A., W�lfing, P., Kersting, C., Vloet, A., B�cker, W., Kiesel, L., Beier, H. M., & Alfer, J. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-1668-2 · Cited by 228
Evolving anticancer drug valproic acid: Insights into the mechanism and clinical studies
Blaheta, R. A., Michaelis, M., Driever, P. H., & Cinatl, J. (2005) · Medicinal Research Reviews · doi:10.1002/med.20027 · Cited by 198
Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis
Kwon, H. J., Kim, M. S., Kim, M. J., Nakajima, H., & Kim, K. (2002) · International Journal of Cancer · doi:10.1002/ijc.1602 · Cited by 171
Roy, S., Packman, K. E., Jeffrey, R., & Tenniswood, M. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401581 · Cited by 171
Andrén, O., Fall, K., Franzén, L., Andersson, S.-O., Johansson, J.-E., & Rubin, M. A. (2006) · Journal of Urology · doi:10.1016/s0022-5347(05)00734-2 · Cited by 166
Mie Lee, Y., Kim, S.-H., Kim, H.-S., Jin Son, M., Nakajima, H., Jeong Kwon, H., & Kim, K.-W. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02787-0 · Cited by 165
Kuefer, R., Hofer, M. D., Altug, V., Zorn, C. S., Genze, F., Kunzi‐Rapp, K., Hautmann, R. E., & Gschwend, J. E. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601510 · Cited by 152
Takai, N., Kawamata, N., Gui, D., SAID, J. W., Miyakawa, I., & Koeffler, H. P. (2004) · Cancer · doi:10.1002/cncr.20709 · Cited by 128
Gediya, L. K., Chopra, P., Purushottamachar, P., Maheshwari, N., & Njar, V. C. O. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058214k · Cited by 98
Richon, V. M., Zhou, X., Rifkind, R. A., & Marks, P. A. (2001) · Blood Cells Molecules and Diseases · doi:10.1006/bcmd.2000.0376 · Cited by 97
Uchida, H., Maruyama, T., Nagashima, T., Asada, H., & Yoshimura, Y. (2005) · Endocrinology · doi:10.1210/en.2005-0359 · Cited by 86
Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials
Kim, S. H., Ahn, S.-H., Han, J., Lee, H. W., Lee, H. Y., Lee, Y., Kim, M. R., Kim, K. W., Kim, W. B., & Hong, S. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.01.149 · Cited by 77
Waltregny, D., North, B. J., Mellaert, F. V., de Leval, J., Verdin, E. M., & CASTRONOVO, V. (2004) · PubMed · doi:10.4081/897 · Cited by 77
Thelen, P., Schweyer, S., Hemmerlein, B., Wuttke, W., Seseke, F., & Ringert, R.-H. (2004) · International Journal of Oncology · doi:10.3892/ijo.24.1.25 · Cited by 71
Rombouts, K., Knittel, T. E., Machesky, L. M., Braet, F., Wielant, A., Hellemans, K., Bleser, P. D., Gelman, I. H., Ramadori, G. P., & Geerts, A. E. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00275-1 · Cited by 68
Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells
Frønsdal, K. B., & Saatcioglu, F. (2004) · The Prostate · doi:10.1002/pros.20140 · Cited by 67
Klisovic, D. D., Klisovic, M. I., Effron, D., Liu, S., Marcucci, G., & Katz, S. E. (2005) · Melanoma Research · doi:10.1097/00008390-200506000-00002 · Cited by 31
The application of epigenetic modifiers on the treatment of prostate and bladder cancer
Zhang, Z., Karam, J. A., Frenkel, E. P., Sagalowsky, A. I., & Hsieh, J. (2006) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2005.11.004 · Cited by 24
Cited by
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Li, Y., & Seto, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026831 · Cited by 1,284
HDAC family: What are the cancer relevant targets?
Witt, O., Deubzer, H. E., Milde, T., & Oehme, I. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.08.016 · Cited by 1,069
Suraweera, A., O’Byrne, K. J., & Richard, D. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00092 · Cited by 669
HDAC expression and clinical prognosis in human malignancies
Weichert, W. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.10.047 · Cited by 409
Self-citation
Metadata
- Authors
- Weichert, W., Röske, A., Gekeler, V, Beckers, T., Stephan, C., Jung, K., Fritzsche, F. R., Niesporek, S., Denkert, C., Dietel, M., & Kristiansen, G.
- Venue
- British Journal of Cancer
- Published
- 2008-01-22
- Volume
- 98
- Issue
- 3
- Pages
- 604-610
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2039139796
- Cited by
- 477
- References
- 34
- FWCI
- 12.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.